ALSO NOTED: FDA OKs vitamin C trial; EC approves Elaprase; and much more...

> Cancer Treatment Centers of America say that it has won FDA approval to mount a clinical trial of intravenous vitamin C as a cancer therapy. Report

> The European Commission has granted marketing approval to Shire's Elaprase for patients with Hunter syndrome. Report

> Rockville, MD-based Neuralstem has executed an exclusive license agreement to Biomedical Research Models for the development of Neuralstem compounds to treat certain cognitive and neurological impacts of diabetes. Release

> Ark Therapeutics announced that the FDA had agreed that a single Phase III trial of its Trinam gene therapy product will suffice for a marketing application. Report

> Entelos is buying an option from Johnson & Johnson Pharmaceutical Research & Development for an exclusive worldwide license to develop selective progesterone-receptor modulators. Report

> Researchers at the University of Pennsylvania School of Medicine have reported significant progress in demonstrating the utility of a new type of cholesterol therapy. Report

> Oxford University's Leonard Seymour and a group of his colleagues are preparing to move a new approach to fighting cancer into human trials. They've been working on viruses that target cancer cells in the hope that the new approach could be used to replace chemotherapy, which has a host of harsh side effects. Report

> A new survey published in Consumer Reports magazine finds that 78 percent of the physicians surveyed say their patients have asked for drugs advertised on TV. Report

And Finally... New research indicates that mating with flashier mates may reduce their offspring's ability to fight off pathogens. Release